FORMA Therapeutics, Inc. Company Profile

21:52 EDT 24th March 2018 | BioPortfolio

News Articles [738 Associated News Articles listed on BioPortfolio]

FORMA Therapeutics Appoints Christine Bellon, Ph.D., J.D., General Counsel and Corporate Secretary

FORMA Therapeutics announced today that Christine (Chris) P. Bellon, Ph.D., J.D., has been appointed to the position of Senior Vice President, General Counsel and Corporate Secret...

MiNA enters NASH deal with Boehringer

Boehringer Ingelheim and MiNA Therapeutics signed an approximately $355.1 million deal to develop drugs that combat the forma -More- 

Global Veterinary Therapeutics Market to Mark CAGR of 6.0% Over Next 10 Years - announces publication of its recently generated research report titled, "GlobalVeterinary Therapeutics MarketBy Type (Therapeutics Drugs, Therapeutics Vaccines, Feed Additives The...

TCT: Transcatheter Repair Works for Functional Tricuspid Regurgitation

(MedPage Today) -- Forma, Cardioband promising for secondary TR in first-in-human studies

What You Need to Know About Indalo Therapeutics

Indalo Therapeutics is based in St. Louis and was formed in October 2016 from the merger of Antegrin Therapeutics and Cascadia Therapeutics.

Capricor Therapeutics to Present at the Piper Jaffray Healthcare Conference

About Capricor Therapeutics Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biolog...

Technical Perspectives on Argos Therapeutics, Omeros, Regulus Therapeutics, and Rhythm Pharma

Argos Therapeutics Durham, North Carolinaheadquartered Argos Therapeutics Inc.'s stock finished last Friday's session 3.20% higher at $0.15. A total volume of 1.81 million Read more...

Proteostasis Therapeutics Announces Withdrawal of Equity Offering Due to Market Conditions

About Proteostasis Therapeutics, Inc. Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis (CF) and other di...

PubMed Articles [412 Associated PubMed Articles listed on BioPortfolio]

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

The 'forma specialis' issue in Fusarium: A case study in Fusarium solani f. sp. pisi.

The Fusarium solani species complex (FSSC) has been studied intensively but its association with legumes, particularly under European agro-climatic conditions, is still poorly understood. In the prese...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Introduction to Volume 1 of JOPT Special Issue.

Eyes on New Product Development: Preclinical Research.

Clinical Trials [135 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1207 Associated Companies listed on BioPortfolio]

FORMA Therapeutics

FORMA Therapeutics unlocks intractable targets to create transformative small molecule therapies. The Company is achieving this by applying its proprietary cell-based screening, s...

FORMA Therapeutics, Inc.

FORMA Therapeutics Holdings, LLC

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

More Information about "FORMA Therapeutics, Inc." on BioPortfolio

We have published hundreds of FORMA Therapeutics, Inc. news stories on BioPortfolio along with dozens of FORMA Therapeutics, Inc. Clinical Trials and PubMed Articles about FORMA Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of FORMA Therapeutics, Inc. Companies in our database. You can also find out about relevant FORMA Therapeutics, Inc. Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record